Search
Standards for functional precision medicine project update, December 2023
A project update from Prof Philipp Staber. We're confident that we'll successfully finish our SWG-initiated small research project, ‘standards for functional precision medicine (StFPM),’ within the next six months.
Read moreWithout access to treatment, can we truly innovate in rare diseases?
Interview with Giampaolo Merlini
There have been many developments on rare diseases since the EU Orphan Medicinal Products Regulation came into force in 2000. As the European Commission is evaluating its effectiveness, EHA discussed with Prof.
Implementation of the new EU Regulation for In Vitro Diagnostic Medical Devices: a ticking time bomb for the diagnostic sector.
Urgent actions are needed now to prevent a collapse of diagnostic testing.
Read moreTackling Sickle Cell Disease: the need for a European approach
Elvie Ingoli, president of the German association of SCD and thalassemia patients, at the 7th EAPM Presidency Conference in Brussels. Sickle Cell Disease (SCD) is relatively new to many parts of Europe.
Read moreEHA leads Tutorial in Kazakhstan for better understanding of lymphomas
EHA, in collaboration with the Kazakhstan Cancer Society (KCS) and Kazakh Institute of Oncology and Radiology (KazIOR), organized its very first tutorial together on March 14-16 in Almaty, Kazakhstan.
Read moreMajor changes needed for patients to benefit from precision medicine
Precision medicine approaches the treatment of a disease via an individual’s genes, environment, and lifestyle.
Read moreEHA in the BioMed Alliance: joining forces for biomedical research
At a recent meeting at the European Parliament, Prof.
Read moreEnabling the spread of good research – a day in the life of an Editor-in-Chief
Most conversations with the Editor of a scientific journal usually revolve around the acceptance (hooray!) or rejection (oh no!) of our research work.
Read moreASCERTAIN: EHA joins consortium aiming for better pricing and reimbursement models
November 28, 2022
EHA is a partner in the ASCERTAIN consortium which will develop models for the pricing, cost-benefit assessment, and reimbursement of innovative health technologies in Europe.
- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- »